{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05399277",
            "orgStudyIdInfo": {
                "id": "21-006724"
            },
            "organization": {
                "fullName": "Mayo Clinic",
                "class": "OTHER"
            },
            "briefTitle": "Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion (CAPITAL-RAPTOR)",
            "officialTitle": "Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion (CAPITAL-RAPTOR)",
            "therapeuticArea": [
                "Other"
            ],
            "study": "rivaroxaban-post-transradial-access-for-the-prevention-of-radial-artery-occlusion-capital-raptor"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-05-17",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-09",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-09",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-05-26",
            "studyFirstSubmitQcDate": "2022-05-26",
            "studyFirstPostDateStruct": {
                "date": "2022-06-01",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-09",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-10",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Trevor J. Simard",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "Mayo Clinic"
            },
            "leadSponsor": {
                "name": "Mayo Clinic",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Ottawa Heart Institute Research Corporation",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "Transradial access (TRA) is the preferred vascular access site for invasive coronary angiography. TRA is limited by blockage of the radial artery post-procedurally, preventing future use of TRA. This is referred to as radial artery occlusion (RAO) and occurs in \\~5% of cases. While intraprocedural anticoagulation has been studied extensively to mitigate this complication, oral anticoagulation post-TRA has not. The investigators will assess the impact of a one-week course of rivaroxaban post-TRA to reduce the rate of ultrasound-defined RAO at 30 days."
        },
        "conditionsModule": {
            "conditions": [
                "Radial Artery Occlusion"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "PREVENTION",
                "maskingInfo": {
                    "masking": "SINGLE",
                    "whoMasked": [
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 700,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Rivaroxaban Group",
                    "type": "EXPERIMENTAL",
                    "description": "Subjects will receive rivaroxaban 15mg tablet to be taken orally once daily for 7 days following transradial access.",
                    "interventionNames": [
                        "Drug: Rivaroxaban"
                    ]
                },
                {
                    "label": "Standard of Care Group",
                    "type": "NO_INTERVENTION",
                    "description": "Subjects will receive the usual standard of care following transradial access."
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Rivaroxaban",
                    "description": "15mg oral daily for 7 days",
                    "armGroupLabels": [
                        "Rivaroxaban Group"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Primary Efficacy Outcome - Radial Artery Occlusion",
                    "description": "Number of subjects to have a radial artery occlusion (RAO) at 30 days post-transradial access (TRA) as determined by Doppler ultrasound assessment.",
                    "timeFrame": "30 days"
                },
                {
                    "measure": "Primary Safety Outcome - Major Bleeding",
                    "description": "Number of subjects to experience major bleeding as defined by the International Society on Thrombosis and Haemostasis (ISTH)",
                    "timeFrame": "30 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "All-Cause Mortality",
                    "description": "Death from any cause as determined by the treating physician",
                    "timeFrame": "30 days"
                },
                {
                    "measure": "Stroke (ischemic or uncertain)",
                    "description": "Stroke (ischemic or uncertain) as defined by a treating neurologist",
                    "timeFrame": "30 days"
                },
                {
                    "measure": "Stroke (hemorrhagic)",
                    "description": "Stroke (hemorrhagic) as defined by a treating neurologist",
                    "timeFrame": "30 days"
                },
                {
                    "measure": "Fatal bleeding",
                    "description": "Bleeding resulting in death as defined by treating physician",
                    "timeFrame": "30 days"
                },
                {
                    "measure": "Symptomatic bleeding in a critical area or organ",
                    "description": "Intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial bleeding or intramuscular bleeding with compartment syndrome",
                    "timeFrame": "30 days"
                },
                {
                    "measure": "Bleeding requiring medical attention",
                    "description": "Any bleeding that requires participant to seek medical attention",
                    "timeFrame": "30 days"
                },
                {
                    "measure": "GUSTO bleeding criteria",
                    "description": "Bleeding as defined by the Global Utilization Of Streptokinase And Tpa For Occluded Arteries (GUSTO) criteria",
                    "timeFrame": "30 days"
                },
                {
                    "measure": "TIMI bleeding criteria",
                    "description": "Bleeding as defined by the Thrombolysis in Myocardial Infarction (TIMI) criteria",
                    "timeFrame": "30 days"
                },
                {
                    "measure": "BARC bleeding criteria",
                    "description": "Bleeding as defined by the Bleeding Academic Research Consortium (BARC) criteria",
                    "timeFrame": "30 days"
                },
                {
                    "measure": "Myocardial infarction",
                    "description": "Myocardial infarction as defined by the third universal definition of myocardial infarction.",
                    "timeFrame": "30 days"
                },
                {
                    "measure": "Stent thrombosis",
                    "description": "Stent thrombosis as determined by the academic research consortium criteria.",
                    "timeFrame": "30 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria\n\n* Willing and able to provide written informed consent\n* Age \u2265 18 years\n* Diagnostic coronary angiography/left heart catheterization or percutaneous coronary intervention via the transradial approach\n\nExclusion Criteria\n\n* Presence of a palpable hematoma or clinical concern of hemostasis at the transradial access site in which bleeding risk would be prohibitive\n* Access or attempted access site - including contralateral radial artery, brachial artery, or femoral artery or vein as switching of access could be attributed to arterial injury\n* Planned staged procedure, coronary artery bypass grafting or noncardiac surgery, within 30 days\n* Pregnant or lactating females\n* Contraindication or high risk of bleeding with anticoagulation\n\n  1. bleeding requiring medical attention in the previous 6 months\n  2. thrombocytopenia (platelets\\<50 x 109/L)\n  3. any prior intracranial hemorrhage\n  4. use of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention\n  5. administration of thrombolytic therapy in the preceding 24 hours\n  6. use of regular non-steroidal anti-inflammatory medications excluding Aspirin \\<100mg/day\n  7. ischemic stroke or transient ischemic attack diagnosed in the last 3 months\n* Cardiogenic shock\n* Ventricular arrhythmias refractory to treatment\n* Liver dysfunction (Child-Pugh class B or C)\n* Unexplained anemia with a Hgb below 100 g/L\n* History of medication noncompliance or risk factor for noncompliance\n* Active malignancy\n* Allergy to rivaroxaban\n* Another indication for anticoagulation\n* Strong CYP3A4 and P-glycoprotein inhibitor use which increase rivaroxaban levels (ketoconazole, itraconazole, lopinavir/ritonavir, ritonavir, diltiazem, verapamil and conivaptan, carbamazepine, phenytoin, rifampin, St.John's wort)\n* Life expectancy \\<30 days\n* Women capable of pregnancy not on birth control\n* Chronic kidney disease with creatinine clearance of less than 30mL/min\n* History of antiphospholipid syndrome, in particular triple positive (lupus anticoagulant, anticardiolipin antibodies, and anti-beta 2-glycoprotein I antibodies)",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Sarah R Devamani",
                    "role": "CONTACT",
                    "phone": "(507) 255-0876",
                    "email": "Devamani.Sarah@mayo.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Trevor Simard, MD",
                    "affiliation": "Mayo Clinic",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Mayo Clinic Rochester",
                    "status": "RECRUITING",
                    "city": "Rochester",
                    "state": "Minnesota",
                    "zip": "55905",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sarah Devamani",
                            "role": "CONTACT",
                            "phone": "507-255-0876",
                            "email": "Devamani.Sarah@mayo.edu"
                        },
                        {
                            "name": "Trevor Simard, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.02163,
                        "lon": -92.4699
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001157",
                    "term": "Arterial Occlusive Diseases"
                }
            ],
            "ancestors": [
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4465",
                    "name": "Arterial Occlusive Diseases",
                    "asFound": "Artery Occlusion",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000069552",
                    "term": "Rivaroxaban"
                }
            ],
            "ancestors": [
                {
                    "id": "D000065427",
                    "term": "Factor Xa Inhibitors"
                },
                {
                    "id": "D000000991",
                    "term": "Antithrombins"
                },
                {
                    "id": "D000015842",
                    "term": "Serine Proteinase Inhibitors"
                },
                {
                    "id": "D000011480",
                    "term": "Protease Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000925",
                    "term": "Anticoagulants"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M463",
                    "name": "Rivaroxaban",
                    "asFound": "Consent",
                    "relevance": "HIGH"
                },
                {
                    "id": "M30513",
                    "name": "Factor Xa Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4307",
                    "name": "Antithrombins",
                    "relevance": "LOW"
                },
                {
                    "id": "M4306",
                    "name": "Antithrombin III",
                    "relevance": "LOW"
                },
                {
                    "id": "M14343",
                    "name": "Protease Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M18391",
                    "name": "Serine Proteinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M19609",
                    "name": "HIV Protease Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4244",
                    "name": "Anticoagulants",
                    "relevance": "LOW"
                },
                {
                    "id": "T18",
                    "name": "Serine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "AnCoag",
                    "name": "Anticoagulants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "AA",
                    "name": "Amino Acids"
                }
            ]
        }
    },
    "hasResults": false
}